Skip to main content
. 2019 Mar 8;60(1):14–24. doi: 10.1002/mus.26447

Figure 2.

Figure 2

Patient disposition through December 31, 2017. In total, 117 patients enrolled in the open‐label study, of whom 56 had received eculizumab and 61 had received placebo during REGAIN. As of December 31, 2017, twenty‐seven patients had discontinued, 5 patients had completed the study, and 85 patients were continuing in the study.